Posted inCardiology Clinical Updates Gastroenterology news
Gut Microbiota-Derived Imidazole Propionate as a Predictor of Cardiometabolic Risk in Coronary Artery Disease: Evidence and Clinical Implications
Emerging evidence identifies circulating imidazole propionate, a gut microbiota-derived metabolite, as an independent predictor of major adverse cardiovascular events in patients with coronary artery disease, offering novel insights into personalized risk stratification and therapeutic targets.